ClinicalTrials.gg
CompletedNCT04234204Moonlight 1Updated Jan 31, 2025

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women in Asia Going Through Menopause

A Phase 3 interventional study of Fezolinetant and Placebo in Hot Flashes, sponsored by Astellas Pharma China, Inc.. Completed at 48 sites in 3 countries. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-31.

Sponsored by Astellas Pharma China, Inc. (part of Astellas Pharma Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing fezolinetant in Hot Flashes — 4 open to participants now, 5 under way, 4 of them phase 3. fezolinetant · Hot Flashes.

Enrollment
7th of 16
302 · median 249
Started
2020
with 1 other
Phase 3
10 of 16
2 open now
Registered
5th of 16
by date
Lead sponsor
2 of 16
Astellas Pharma China, Inc.

Among the 16 studies testing fezolinetant in Hot Flashes, this one is the 7th largest by enrollment, is one of 2 that started in 2020, is one of 10 in phase 3, and was the 5th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

4 of the 16 studies testing fezolinetant in Hot Flashes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fezolinetant

fezolinetant: first FDA approval 2023 (VEOZAH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing fezolinetant in Hot Flashes, or all of them as a file.
02

Study summary

This study is for women in menopause with moderate to severe hot flashes. Menopause, a normal part of aging, is the time of a woman's last period. Hot flashes can interrupt a woman's daily life.

The study treatments are fezolinetant (1 tablet) once a day or placebo (1 tablet) once a day. (Placebo is a dummy treatment that looks like medicine but does not have any medicine in it.) The study will compare fezolinetant and placebo after 4 and 12 weeks of dosing. The study will see if fezolinetant reduces the number of hot flashes. And the study will see if fezolinetant reduces the severity of the hot flashes.

Women in the study will receive an electronic handheld device at the first study visit. (It is similar to a smart phone.) Each day of the study, study participants will use this to record their hot flashes. Their record for the 10 days before the start of study treatment will be checked. They can remain in the study if their record shows 7 or 8 moderate to severe hot flashes per day (50 or more per week).

Next, they will be picked for 1 of the 2 study treatments (fezolinetant or placebo) by chance alone. It is like flipping a coin.

The study participants will take study treatment for 24 weeks. The first 12 weeks of study treatment are "double-blinded." That means that the study participants and the study doctors do not know who takes which of the study treatments (fezolinetant or placebo) during that time. The last 12 weeks of study treatment are "noncontrolled." That means that each study participant and the study doctors know which study treatment that study participant takes during that time. Women who take fezolinetant during the first 12 weeks will continue to take fezolinetant. Women who take placebo during the first 12 weeks will start taking fezolinetant.

At weeks 2, 4, 8, 12, 14, 16, 20 and 24, the study participants will go to the hospital or clinic for a check-up. They will be asked about medications, side effects and how they feel. Other checks will include physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine will be collected for laboratory tests. Study participants will complete questionnaires that are about how hot flashes affect their daily life. Study participants who still have their uterus will have the following 2 tests done at the first and last study visits if they meet the criteria. One of the 2 tests is endometrial biopsy.

This test involves removing a small amount of tissue from the inside lining of the uterus. The tissue is then checked under a microscope. The other test is transvaginal ultrasound. This test uses sound waves to create pictures of the organs in the pelvis. The sound waves are transmitted by a probe (transducer), which is placed inside the vagina. Study participants may have a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not have this test done in the last 12 months will have it done at the first study visit. They will have it done at the last study visit if they are due for their screening mammogram and their own doctor agrees.

The last check-up at the hospital or clinic will be 3 weeks after the last dose of study treatment.

Read the detailed description

This study will consist of a screening period and a 24-week treatment period. Safety follow up will occur 3 weeks after the last dose of study drug.

03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • ESN364
  • menopause
  • fezolinetant
  • vasomotor symptoms
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a ≥16 kg/m\^2 and ≤38 kg/m\^2 (extremes included) at screening visit.
  • Participant must be seeking treatment or relief for vasomotor symptoms (VMS) associated with menopause and confirmed as menopausal per 1 of the following criteria at the screening visit:

    • Spontaneous amenorrhea for ≥ 12 consecutive months
    • Spontaneous amenorrhea for ≥ 6 months with biochemical criteria of menopause (follicle stimulating hormone [FSH] > 40 IU/L); or
    • Having had bilateral oophorectomy ≥ 6 weeks prior to the screening visit (with or without hysterectomy)
    • FSH > 40 IU/L if participants received hysterectomy but still have ovary
  • Within the 10 days prior to randomization, participant must have a minimum average of 7 to 8 moderate to severe HFs (VMS) per day, or 50 to 60 per week.
  • Participant is in good general health as determined on the basis of medical history and general physical examination, including a bimanual clinical pelvic examination and clinical breast examination devoid of relevant clinical findings, performed at the screening visit; hematology and biochemistry parameters, pulse rate and/or blood pressure, and (ECG) within the reference range for the population studied, or showing no deviations.
  • Participant has documentation of a normal/negative or no clinically significant findings mammogram (or echo) (e.g. \< BI-RADS class 4; obtained at screening or within the prior 12 months of study enrollment). Appropriate documentation includes a written report or an electronic report indicating normal/negative or no clinically significant mammographic findings.
  • Participant is willing to undergo a transvaginal ultrasound (TVU) to evaluate the uterus and ovaries at screening and week 24 (end-of-treatment), and for participants who are withdrawn from the study prior to completion, a TVU at the early discontinuation (ED) visit. This is not required for participants who have had a partial (supra-cervical) or full hysterectomy.
  • Participant is willing to undergo an endometrial at screening, and at week 24 (end of treatment) or early discontinuation (ED) visit if endometrial thickness >4mm indicated by TVU; and participant is willing to undergo an endometrial biopsy at any time during the study in the case of uterine bleeding. This is not required for participants who have had a partial (supracervical) or full hysterectomy. A biopsy with insufficient material for evaluation, or unevaluable material, is acceptable provided the endometrial thickness is no greater than 8 mm.
  • Participant has documentation of a normal or not clinically significant Pap test (or equivalent cervical cytology within the previous 12 months of study enrollment or at screening. This is not required for participants who have had a full hysterectomy.
  • Participant has a negative urine pregnancy test at screening, this is not required for participants who have had a full hysterectomy.
  • Participant has negative serology panel [i.e., negative surface antigen (HBsAg) and negative virus antibody (HCVAb) screens] at screening.
  • Participant agrees not to participate in another interventional study while participating in the present study.

Exclusion criteria

Exclusion Criteria:

  • Participant uses a prohibited therapy (strong and moderate cytochrome P450 1A2 [CYP1A2] inhibitors, hormone replacement therapy [HRT], hormonal or any treatment for VMS [prescription, over the counter, or herbal]) or is not willing to wash out and discontinue use of such drugs for the full duration of study conduct.
  • Participant has known substance abuse or alcohol addiction within 6 months of screening.
  • Participant has a history of a malignant tumor, except for non- basal cell carcinoma of the skin.
  • Participant has uncontrolled hypertension, defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure as ≥ 90 mmHg based on an average of 2 to 3 readings within the screening period. Participants with a medical history of hypertension who are well controlled may be enrolled. Participants who do not meet these criteria may, at the discretion of the investigator, be re-assessed after initiation or review of antihypertensive measures.
  • Participant has a history of severe allergy, , or intolerance to drugs in general, including the study drug and any of its .
  • For Participants with a uterus: Participant has an unacceptable result from the TVU assessment at screening, i.e. full length of endometrial cavity cannot be visualized or presence of a finding.
  • For Participants with a uterus and endometrial thickness >4mm indicated by TVU: Participant has an endometrial confirming presence of disordered proliferative endometrium, endometrial hyperplasia, endometrial cancer, or other clinically significant at screening. A biopsy with insufficient material for evaluation, or unevaluable material is acceptable provided the endometrial thickness is no greater than 8 mm.
  • Participant has a history within the last 6 months of undiagnosed uterine bleeding.
  • Participant has a history of seizures or other convulsive disorders.
  • Participant has a medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], endocrine, or gynecological disease) or that could confound interpretation of the study outcome.
  • Participant has active liver disease, jaundice, elevated liver aminotransferases ( [ALT] or aspartate aminotransferase [AST]), elevated total or direct , elevated or elevated alkaline phosphatase (ALP). Patients with mildly elevated ALT or AST up to \< 1.5 × the (ULN) can be enrolled if total and direct bilirubin are normal. Patients with mildly elevated ALP (up to \< 1.5 × ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Patients with Gilbert's syndrome with elevated total bilirubin may be enrolled as long as hemolysis is ruled out (i.e. direct bilirubin, and reticulocytes are normal).
  • Participant has creatinine > 1.5 × ULN; or estimated (eGFR) using the Modification of Diet in Renal Disease formula ≤ 59 mL/min/1.73 m\^2 at screening.
  • Participant has a positive result for (HIV) at screening.
  • Participant has a history of suicide attempt or suicidal behavior within the last 12 months or has suicidal ideation within the last 12 months (a response of "yes" to question 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale [C-SSRS]), or who is at significant risk to commit suicide at screening and at visit 2.
  • Participant has previously been enrolled in a clinical trial with fezolinetant.
  • Participant has received study drug within 28 days or 5 half-lives, whichever is longer, prior to screening.
  • Participant is unable or unwilling to complete the study procedures.
  • Participant has any condition which makes the subject unsuitable for study participation.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    Fezolinetant group

    Participants will receive fezolinetant once daily for 24 weeks.

    Drug: Fezolinetant

  • Placebo comparator
    Placebo group

    Participants will receive matching placebo for 12 weeks, and then receive fezolinetant for 12 weeks once daily.

    Drug: Fezolinetant · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change from baseline in the frequency of moderate to severe vasomotor symptoms (VMS)

    Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day.

    Time frame: Baseline to Week 4

  2. Mean change from baseline in the frequency of moderate to severe VMS

    Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day.

    Time frame: Baseline to Week 12

  3. Mean change from baseline in the severity of moderate to severe VMS

    The severity of VMS will be calculated using a weighted average of VMS events.

    Time frame: Baseline to Week 4

  4. Mean change from baseline in the severity of moderate to severe VMS

    The severity of VMS will be calculated using a weighted average of VMS events.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Mean change from baseline to each week in the frequency of moderate and severe VMS

    Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day.

    Time frame: Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 11, 12

  2. Mean change from baseline to each week in the severity of moderate and severe VMS

    The severity of VMS will be calculated using a weighted average of VMS events.

    Time frame: Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 11, 12

  3. Mean percent reduction from baseline to each week in the frequency of moderate and severe VMS

    Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day.

    Time frame: Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 11, 12

  4. Percent reduction ≥50% from baseline to each week in the frequency of moderate and severe VMS

    Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Ratio of the participants with ≥50% reduction in frequency will be reported.

    Time frame: Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 11, 12

  5. Percent reduction at 100% from baseline to each week in the frequency of moderate and severe VMS

    Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day. Ratio of the participants with ≥ 100% reduction in frequency will be reported.

    Time frame: Baseline to Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 11, 12

  6. Mean change from baseline in the frequency of moderate to severe VMS

    Frequency of moderate or severe VMS events will be calculated as the sum of moderate or severe VMS events per day.

    Time frame: Baseline to Week 24

  7. Mean change from baseline in the severity of moderate to severe VMS

    The severity of VMS will be calculated using a weighted average of VMS events.

    Time frame: Baseline to Week 24

  8. Number of Participants With Adverse Events

    An adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to 27 Weeks

  9. Number of Participants With Adverse Events Based on Severity

    An AE is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Up to 27 Weeks

  10. Change From Baseline in Endometrial Thickness

    Endometrial thickness is a measure of how thick the lining of the uterus is. Endometrial thickness will be measured by transvaginal ultrasound (TVU).

    Time frame: Baseline and Week 24

  11. Percentage of Participants With Endometrial Hyperplasia and/or Endometrial Cancer

    Endometrial hyperplasia is thickening of the lining of the uterus. Endometrial cancer is cancer of the lining of the uterus.

    Time frame: Up to 24 Weeks

  12. Number of Participants With Vital Sign Abnormalities and/or Adverse Events

    Number of participants with potentially clinically significant vital sign values will be reported.

    Time frame: Up to 27 Weeks

  13. Number of Participants With Electrocardiogram (ECG) Abnormalities and/or Adverse Events (AEs)

    Number of participants with potentially clinically significant ECG values will be reported.

    Time frame: Up to 27 Weeks

  14. Number of Participants With Laboratory Value Abnormalities and/or Adverse Events (AEs)

    Number of participants with potentially clinically significant laboratory values will be reported.

    Time frame: Up to 27 Weeks

  15. Change From Baseline in Bone Specific Alkaline Phosphatase (BSAP)

    Change from baseline in serum concentrations of BSAP will be reported.

    Time frame: Baseline, Week 24 and Week 27

  16. Change From Baseline in Procollagen Type 1 Aminoterminal Propeptide (P1NP)

    Change from baseline in serum concentrations of P1NP will be reported.

    Time frame: Baseline, Week 24 and Week27

  17. Change From Baseline in Carboxy-Terminal Telopeptide of Type I Collagen (CTX)

    Change from baseline in serum concentrations of CTX will be reported.

    Time frame: Baseline, Week 24 and Week 27

  18. Pharmacokinetics (PK) of Fezolinetant in Plasma: Concentration

    Concentration will be recorded from the PK plasma samples collected.

    Time frame: Week 4, Week 12, Week 16, Week 24

  19. Pharmacokinetics (PK) of Fezolinetant Metabolite ES259564 in Plasma: Concentration

    Concentration will be recorded from the PK plasma samples collected.

    Time frame: Week 4, Week 12, Week 16, Week 24

  20. Change from Baseline in Sex Hormones

    Change from baseline in serum concentration of sex hormones will be reported.

    Time frame: Baseline, Week 4, Week 12, Week 24 and Week 27

  21. Change from Baseline in Sex Hormone-Binding Globulin (SHBG)

    Change from baseline in serum concentration of SHBG will be reported.

    Time frame: Baseline, Week 4, Week 12, Week 24 and Week 27

07

Study locations

48 sites
  • Site CN86001
    Beijing, China
  • Site CN86002
    Beijing, China
  • Site CN86017
    Beijing, China
  • Site CN86030
    Beijing, China
  • Site CN86022
    Changchun, China
  • Site CN86009
    Changsha, China
  • Site CN86037
    Chengdu, China
  • Site CN86006
    Guangzhou, China
  • Site CN86019
    Guangzhou, China
  • Site CN86042
    Guangzhou, China
  • Site CN86043
    Guangzhou, China
  • Site CN86018
    Guiyang, China
  • Site CN86025
    Hangzhou, China
  • Site CN86034
    Hangzhou, China
  • Site CN86027
    Kunming, China
  • Site CN86005
    Liuzhou, China
  • Site CN86004
    Nanjing, China
  • Site CN86011
    Nanjing, China
  • Site CN86035
    Nanjing, China
  • Site CN86026
    Nanning, China
  • Site CN86012
    Shanghai, China
  • Site CN86021
    Shenzhen, China
  • Site CN86007
    Shijiazhuang, China
  • Site CN86023
    Taiyuan, China
  • Site CN86031
    Taiyuan, China
  • Site CN86015
    Tianjin, China
  • Site CN86029
    Tianjin, China
  • Site CN86008
    Wuhan, China
  • Site CN86041
    Yangzhou, China
  • Site CN86013
    Yinchuan, China
  • Site CN86033
    Zhongshan, China
  • Site KR82013
    Ansan-si, Korea, Republic of
  • Site KR82005
    Busan, Korea, Republic of
  • Site KR82003
    Seongnam-si, Korea, Republic of
  • Site KR82011
    Seongnam-si, Korea, Republic of
  • Site KR82001
    Seoul, Korea, Republic of
  • Site KR82002
    Seoul, Korea, Republic of
  • Site KR82004
    Seoul, Korea, Republic of
  • Site KR82006
    Seoul, Korea, Republic of
  • Site KR82012
    Seoul, Korea, Republic of
  • Site TW88608
    Kaohsiung City, Taiwan
  • Site TW88604
    New Taipei City, Taiwan
  • Site TW88606
    Taichung, Taiwan
  • Site TW88603
    Tainan, Taiwan
  • Site TW88609
    Tainan, Taiwan
  • Site TW88601
    Taipei, Taiwan
  • Site TW88607
    Taipei, Taiwan
  • Site TW88611
    Taipei, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Apr 2022, 25 months.

Of 23 phase 3 interventional studies under Hot Flashes, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 29. This study's 25 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2020
First posted
Jan 21, 2020
StartActual
Mar 17, 2020
Primary completionActual
Apr 20, 2022
CompletionActual
Apr 20, 2022
Last update
Jan 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04234204
Responsible party
Sponsor
First posted
Jan 21, 2020
Start date
Mar 17, 2020
Primary completion
Apr 20, 2022
Completion
Apr 20, 2022
Last update
Jan 31, 2025

Study contacts

Medical Monitor
study director · Astellas Pharma China, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fezolinetant

Start the discussion